ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Late-Breaking 2021"

  • Abstract Number: L11 • ACR Convergence 2021

    Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study

    ELVIRA D'ANDREA1, Rishi Desai2, Mengdong He3, Robert Glynn4, Hemin Lee2, Michael Weinblatt2, Daniel Solomon5 and Seoyoung Kim2, 1Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3UCLA David Geffen School of Medicine, Los Angeles, CA, 4Brigham & Women's Hospital, Boston, MA, 5Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…
  • Abstract Number: L12 • ACR Convergence 2021

    Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function

    Michaela Koehm1, Tanja Rossmanith2, Ann Christina Foldenauer2, Eva Herrmann3, Herbert Kellner4, Uta Kiltz5, Jürgen Rech6, Gerd Burmester7, David Kofler8, Jan Brandt-Jürgens9, Christin Jonetzko10, Harald Burkhardt1 and Frank Behrens1, 1Rheumatology Goethe-University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 2Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 3Institute for Biostatistics and Mathematical Modeling, Goethe-Universität Frankfurt, Frankfurt, Germany, 4Praxis Prof. Dr. Kellner, München, Germany, 5Rheumazentrum Ruhrgebiet, Herne, Germany, 6Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, 7Charite Universitaetsmedizin Berlin, Germany and DRFZ, Berlin, Germany, 8Universitätsklinikum Köln, Med. Klinik I f. Innere Medizin Immunologische Ambulanz, Köln, Germany, 9Rheumatologische Schwerpunktpraxis im Ärztehaus am Walter-Schreiber-Platz, Berlin, Germany, 10Fraunhofer Insitute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany

    Background/Purpose: Methotrexate (MTX) is often used as first-line DMARD-therapy in active psoriatic arthritis (PsA). Randomized clinical trials usually require treatment failure or intolerance of csDMARD/MTX…
  • Abstract Number: L13 • ACR Convergence 2021

    Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study

    Cynthia Aranow1, Cornelia Allaart2, Zahir Amoura3, Ian N Bruce4, Patricia Cagnoli5, Richard Furie1, Paul Peter Tak6, Murray Urowitz7, Ronald van Vollenhoven8, Kenneth L Clark6, Mark Daniels9, Norma Lynn Fox10, Yun Irene Gregan10, James Groark11, Robert B Henderson9, Mary Oldham9, Don Shanahan9, Andre van Maurik9, David A Roth10 and YK Onno Teng2, 1Feinstein Institutes for Medical Research, Northwell Health, Great Neck, NY, 2Leiden University Medical Center, Leiden, Netherlands, 3Centre National de reference pour le Lupus, Service de Medecine Interne 2, Institut E3M, Hopital Pitié-Salpétrière, Paris, France, 4NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Trust and Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 5University of Michigan Medical Center, Ann Arbor, MI, 6GlaxoSmithKline (At the time of the author's contribution to this study), Stevenage, United Kingdom, 7Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, 8Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 9GlaxoSmithKline, Stevenage, United Kingdom, 10GlaxoSmithKline, Collegeville, PA, 11GlaxoSmithKline (At the time of the author's contribution to this study), Collegeville, PA

    Background/Purpose: Disease control remains an unmet need in SLE. The rationale for sequential BEL and RTX therapy in SLE was previously published.1 This study evaluated…
  • Abstract Number: L14 • ACR Convergence 2021

    Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis

    David Jayne1, Peter Merkel2, Annette Bruchfeld3, Duvuru Geetha4, Alexandre Karras5, John Niles6 and Pirow Bekker7, 1University of Cambridge, Cambridge, United Kingdom, 2University of Pennsylvania, Philadelphia, PA, 3Linköping University, Linköping, Sweden, 4Johns Hopkins University, Baltimore, MD, 5Hopital Europeen Georges Pompidou, Paris, France, 6Massachusetts General Hospital, Boston, MA, 7ChemoCentryx, Inc., San Carlos, CA

    Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a life- or organ-threatening condition in which patients experience severe inflammation of small blood vessels; renal disease is…
  • Abstract Number: L15 • ACR Convergence 2021

    A Predictive Diagnostic Model for IgA Vasculitis Based on a Metabolomic Approach

    Alexandre Boissais1, Hélène Blasco2, Patrick Emond3, Antoine Lefevre2, Adrien Bigot4, denis Mulleman5, François Maillot4 and Alexandra Audemard-Verger4, 1Medical University of Tours, Tours, France, 2Biochemistry and Molecular Biology Department, Tours, France, 3In vitro Nuclear Medicine Department, Tours, France, 4Department of Internal Medicine, Tours, France, 5Rheumatology Department, Tours, France

    Background/Purpose: IgA vasculitis is a rare systemic disease that is life-threatening mainly due to digestive or renal involvement. To date, there is no reliable diagnostic…
  • Abstract Number: L16 • ACR Convergence 2021

    Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository

    Jasvinder Singh1, Namrata Singh2, Alfred Anzalone3, Amy Olex4, Jing Sun5, Vithal Madhira6 and Rena Patel7, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Washington, Bellevue, WA, 3University of Nebraska, Omaha, NE, 4Virginia Commonwealth University, Richmond, VA, 5Johns Hopkins University, Baltimore, MD, 6Palila Software, Reno, NV, 7Unviersity of Washington, Seattle, WA

    Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology